Further delays risk undermining the health and well-being of the very patients the National Strategy for Drugs for Rare Diseases was intended to assist.
One in 12 Canadians, two-thirds of them children, suffer from a rare disease. IMC is committed to advocating for policies that increase timely access to medicines and treatments for patients suffering from rare diseases.
Canada desperately needs a rare disease strategy that’ll enable better patient care and access to treatment for those living with rare diseases.
Ottawa, March 22, 2023 – Innovative Medicines Canada (IMC) is encouraged by the federal government’s announcement regarding its intentions for […]
This article originally appeared in Maclean’s print and healthinsights.ca on February 16, 2023 Canada desperately needs a rare disease strategy that’ll enable […]
Innovative Medicines Canada provides Health Canada with additional input regarding IMC’s March 2021 consultation submission on drugs for rare diseases.
IMC proposes a value-based, pan-Canadian rare disease strategy, built in collaboration with provinces, patients, clinicians and industry to fill gaps and meet specific needs.
Infographics & Data
Time to Listing: Canada’s public plans cover fewer new medicines and take longer than most OECD countries to approve them
Public plans in Canada cover fewer medicines than in other OECD20 countries and take longer to be approved. For rare-disease medicines, this gap is even larger.
Analysis & Reports
Sorry, no posts were found. Please check again later.